Monday, November 25, 2013

Coal for Christmas: Americans Say Cable TV Holiday Ads Impacts Their Shopping—But Most Admit They Would Like to See More Scrooge-Like Themes in Ads

Coal for Christmas: Americans Say Cable TV Holiday Ads Impacts Their Shopping—But Most Admit They Would Like to See More Scrooge-Like Themes in Ads, New Viamedia Study Finds. Americans ranked their favorite Scroogey scenarios—from naughty kids getting coal to ditching the in-laws.
Full Article Appears Below
SOURCE: Daily Dog, Bulldog Reporter, www.bulldogreporter.com
November 25, 2013 -- Viamedia, a cable industry-focused independent cable rep firm and provider of online advertising services, recently announced its 2013 Holiday Cable Advertising Study, which determined how advertisements on cable TV networks impacts the 89% of Americans who watch cable TV programming. The study examined the positive qualities that make holiday advertisements on cable TV networks most memorable and finally asked what "Scrooge-like" themes, if any, Americans would like to see in holiday advertisements.
A majority of Americans (54%) admitted advertisements on cable TV networks (e.g., ESPN, Lifetime, TNT, A&E, History Channel, CNN) impact their holiday shopping. The demographics most affected were students (75%), men 18–34 (66%) and women (69%) 18–34. The reasons included:  
•   38%—informs me about sales (which was particularly important to 60% students)
•   25%—gives me ideas on what to buy for hard to buy people
•   21%—prompts me to consider shopping at that store or buy products at that store
•   19%—makes me realize how many shopping days are left
•   15%—makes me realize what’s hot
•   8%—makes me shop for myself

An overwhelming majority of Americans (72%) agreed positive qualities make a holiday advertisement on cable TV networks most memorable—especially 82% of households with children. However when it came to what exactly Americans thought of as memorable, Americans were hard-pressed to agree with the number one choice being emotional appeal—with just 18% of Americans naming that trait. Emotional appeal was followed by portrayal of the family with 14%.  Only 13% of households with children said portrayal of family was important.  That was followed by holiday tie-in (14%), feature people like me (8%), play on words like “happy Holidays” (6%) and inclusion of veterans (5%).
A majority Americans (59%) admitted they wanted to see "Scrooge-like" themes in holiday advertisements on cable TV networks—which was especially popular with men (77%) 18-34 and women (75%) 18-34. Americans ranked their favorite Scroogey scenarios—from naughty kids getting coal to ditching the in-laws:
•   27%—how do you react to a present you don’t like
•   25%—the best way to return a bad gift
•   21%—the right way to re-gift
•   19%—naughty kids getting coal for Christmas (24% of households with children said yes – 17% said no)
•   16%—how to shop for people I don’t like
•   14%—what to do with carolers who can’t sing
•   14%—how to shop for myself guilt free
•   13%—how kids can be annoying
•   12%—how to ditch the in-laws
“Viamedia’s 2013 Holiday Cable Advertising Study proves how cable TV advertisements play a key role in how we celebrate the season,” said Becky Jones, vice president marketing and research at Viamedia, in a news release. “Cable TV advertising impacts a majority of Americans—giving gifts ideas and even alerting them to how many shopping days we have left. It’s a good feeling to know that consumers find holiday ads on cable TV to be a meaningful part of their holiday experience. And, just like with the cable TV programs themselves, their opinions of what makes a commercial’s magic ingredient are as broad as their own imaginations.

“We found it surprising that while Americans can’t agree on the magic ingredient that makes a good holiday commercial, they can agree on wanting to see Scrooge-like themes in advertisements.”

Thursday, November 21, 2013

Oncology Clinical Trial News: Phase Ib clinical trial for new cancer therapy for solid tumors


A first-of-its-kind Phase Ib clinical trial -- with Weill Cornell Medical College, Palo Alto Medical Foundation, and MD Anderson Cancer Center -- will study Berg's investigational compound, BPM 31510 (IV Continuous Infusion), as a new cancer therapy for solid tumors. Unlike other clinical trials, this is the first program to focus on the metabolism, or processes, of cancer rather than a specific mutation or target.
Full press release follows.
SOURCE: Berg
Berg Launches First-Ever Stratified Medicine Clinical Trial To Investigate Cancer Metabolism Of Solid Tumors
-- Patients at Cornell, the Palo Alto Medical Foundation, MD Anderson Participate in First Clinical Program to Comprehensively Use Artificial Intelligence --
FRAMINGHAM, Mass., Nov. 21, 2013 /PRNewswire/ -- Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach, today announced  a first-of-its-kind Phase Ib clinical trial with Weill Cornell Medical College, Palo Alto Medical Foundation, and MD Anderson Cancer Center to study its investigational compound, BPM 31510 (IV Continuous Infusion), as a new cancer therapy for solid tumors.
"Unlike other clinical trials, this is the first program to focus on the metabolism, or processes, of cancer rather than a specific mutation or target," said Niven R. Narain, Co-Founder, President and CTO of Berg. "By using big data analytics, we're also able to identify the right type of patients who will respond to the BPM 31510 treatment. Stratifying patients by phenotype is the future of medicine and we want to boldly develop a cancer treatment using this approach"
Peter Yu, MD, Director of Cancer Research at Palo Alto Medical Foundation and incoming president of The American Society of Clinical Oncology (ASCO), will serve as a primary investigator on this trial together with Ralph Zinner, MD at MD Anderson and lead PI, Manish Shah, MD at Weill Cornell Medical College, which is expected to enroll between 300 - 400 oncology patients affected by solid tumors, including those with highly aggressive cancers like pancreatic, triple-negative breast, liver or brain.
BPM 31510 targets the cellular machinery that governs metabolism of cancer cells to alter those cells to behave like normal, healthy cells. The treatment is the first in Berg's pipeline endogenously occurring candidates discovered and developed by the Berg Interrogative BiologyTM platform, an artificial intelligence-based system that uses network biology methodologies to study biological systems.
Through Berg's proprietary Interrogative Biology™ Drug Discovery Platform, this clinical program will establish each patient's molecular and metabolic fingerprint by analyzing multi-omic tissue samples (blood, urine, bone marrow, etc) in real time. This step will allow trial investigators to understand how patients' cells are responding to the treatment to assess the unique characteristics in patients who are responding to the therapy or combinations with BPM 31510.  One very interesting arm of the trial will also assess the effect of "mitochondrial priming" where BPM 31510 will be given for 1 cycle followed by chemotherapy to assess for increased efficacy and potential reduction in chemo-induced side effects.
"It is both a privilege and honor to work with Berg - a forward thinking broad reaching company that is interested in truly moving the bar in medicine in a comprehensive and revolutionary way," said Dr. Manish A. Shah, Associate Professor of Medicine at the Weill Cornell Medical College of Cornell University.  "The goal of this comprehensive and unprecedented evaluation of clinical data, molecular profiles, and patient characteristics - a virtual clinical 'big data' evaluation - is to develop safer, more effective drugs in half the time. Drug development is an arduous process, but with Berg as a partner, it feels like we are on the fast track."
More information about the clinical trials evaluating BPM 31510 also can be found at www.ClinicalTrials.gov.
About BPM 31510
Berg's lead molecular candidate, BPM 31510, is a proprietary formulation of ubidecarenone, an endogenous small molecule responsible for generating cell energy. Preclinical trials indicate that BPM 31510 normalizes the BCL2 protein, which is a key feature in the regulation of cell death and is over-expressed in 60-70% of tumors.
BPM 31510 is being investigated in clinical trials as both a monotherapy and in combination with chemotherapies like gemcitabine, 5FU and docetaxel for its potential to treat numerous cancers, including squamous cell carcinoma and solid tumors. 
About the Berg Interrogative Biology™ Platform
Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.
Using the Interrogative Biology platform, the company has successfully harnessed the ability of its lead oncology candidate, BPM 31510, in development with gemcitabine, to create an anti-cancer effect. Phase 1 and 2 clinical trials of a topical formulation of BPM 31510 for the treatment of skin cancers have completed, as has a Phase 1 dose escalation clinical trial of an intravenous formulation of BPM 31510 for the treatment of solid tumors.
About Berg                            
Berg, the namesake of Carl Berg, is a biopharmaceutical company and parent company to Berg Pharma, Berg Biosystems and Berg Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow. For additional information, visit http://www.bergpharma.com/.

Media Contact: 
Alisha Tischler 
Ogilvy Public Relations 
212-880-5218 
alisha.tischler@ogilvy.com
Investor Contact: 
Tom Smith 
Ogilvy Public Relations 
212-880-5269 
tom.smith@ogilvy.com

SOURCE Berg


Wednesday, November 20, 2013

Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing

Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing.
·      Total Commitment $60 Million.
·      Argos is developing fully personalized immunotherapies for the treatment of cancer and infectious diseases

Full press release follows.

SOURCE: Argos Therapeutics

DURHAM, N.C., Nov. 20, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that on November 4, 2013, the Company increased the size of its previously announced Series E financing by $17.5 million, bringing the total amount of committed funds from $42.5 million to $60 million.
In August 2013, Argos announced the closing of a $42.5 million Series E financing.  The additional $17.5 million investment represents additional commitments from current Argos investors and one new investor. The funds from the Series E financing will be used to support the Company's ongoing ADAPT pivotal Phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). 

"This funding further strengthens our ability to advance our ADAPT clinical trial.  In addition, the company is now better positioned to consider and pursue a range of options to support our global manufacturing and commercialization plans based on the potential of our Arcelis™ technology platform," said Jeff Abbey, Argos' president and chief executive officer.

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.
The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics 
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos' most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
SOURCE Argos Therapeutics Inc.
CONTACT: Andrea Coan, Berry & Company Public Relations, acoan@berrypr.com, (212) 253-8881


Thursday, November 14, 2013

Health Tech Funding News, Acupera secures $6 million in funding

Acupera secures a total of $6 Million in funding, to expand development of its patient care management platform. Acupera's care management platform mines existing electronic medical records to elevate the most important data relevant to improving overall population health.
Full press release appears below.
SOURCE: Acupera
SAN FRANCISCO, Nov. 14, 2013 /PRNewswire/ -- Acupera today announced it secured $2 million in bridge financing from The Whittemore Collection, Ltd. to fund the development of its Population Health and Care Coordination Workflow Management technology. Acupera's solution is designed to maximize patient care effectiveness and efficiency within healthcare organizations. The $2 million is in addition to $4 million previously secured in Series A funding from The Whittemore Collection, Ltd. and Liebkind, LLC, which supported the initial development of Acupera's patient care management platform. Acupera is a privately held technology company, launched in 2011.
 "Acupera enables real-time, cloud-based patient risk stratification, and clinical and behavioral workflow management that enables health care organizations to meet the diverse medical and psycho-social needs of their patient communities," said Dr. Ronald Razmi, CEO of Acupera. "Our technology is designed to easily integrate within existing provider workflows, identify patient-critical needs and rally just the right resources to ensure patient care needs are anticipated and met."
Acupera's care management platform effectively mines existing electronic medical records to elevate the most important data relevant to improving overall population health. With its patient- and user-friendly interface, Acupera is uniquely suited to not only meet the evolving needs of care management teams, but also to engage local patient populations in self-care.
"Acupera is the next step in the digital health revolution and begins to make clinical data actionable," said George Landegger, managing director of The Whittemore Collection, Ltd.
"Acupera is the only solution available today that is suited to address the evolving requirements of growing healthcare organizations," said Hermann Buerger, managing member of Liebkind, LLC. 
 SOURCE Acupera
CONTACT: Claire Baki/ Anne Lundregan, Schwartz MSL, +1.415.512.0770, acupera@schwartzmsl.com